Imidazol- or 1,2,4-triazol-derivatives and their use

1. A compound of Formula I:

or a pharmaceutically acceptable salt or solvate thereof,

wherein:

X is CH or N;

Y is CR 1 or N;

Z is CR 2 or N; with the proviso that Y and Z are not both N;

R 1 and R 2 are, independently of each other, C1-C2-alkoxy or halo;

R 3 is H or methyl;

R 4 is phenyl or pyridinyl, said phenyl or pyridinyl being unsubstituted or substituted by one or more groups selected from the group consisting of halo, C1-C2-alkoxy, and haloalkyl;

R 5 and R 6 are, independently of each other, H, halo or C1-C2-alkyl;

L 2 is O, —C≡C—, CH 2 , NH, NH(CO), (CO)NH, NH(SO 2 ), or (SO 2 )NH

n is an integer from 0 to 4;

A is selected from the group consisting of N(R 7 ) 2 , wherein R 7 is H or linear C1-C4-alkyl, SO 3 H,

wherein m is 3 to 500,

wherein R 8 is linear C1-C4-alkyl and Q − is a counter anion, and

a cyclic moiety selected from the group consisting of

wherein R A is H, OH, C0-C4-alkyl-COOH or C1-C6-alkyl, R B is C1-C6-alkyl optionally substituted with —COOH, R C is C1-C6-alkyl, and Q − is a counter anion; or

L 2 -(CH 2 ) n -A is H.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein

L 2 is O, —C≡C—, CH 2 , NH, NH(CO), (CO)NH, NH(SO 2 ), or (SO 2 )NH

n is an integer from 0 to 4;

A is selected from the group consisting of N(R 7 ) 2 , wherein R 7 is H or linear C1-C4-alkyl, SO 3 H,

wherein m is 3 to 500,

wherein R 8 is linear C1-C4-alkyl and Q − is a counter anion.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein L 2 -(CH 2 ) n -A is H.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein X is CH.

5. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein X is N.

6. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 and R 2 are both methoxy.

7. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are, independently of each other, H, fluoro or methyl.

8. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, having Formula II

or a pharmaceutically acceptable salt or solvate thereof.

9. The compound according to claim 8 , or a pharmaceutically acceptable salt or solvate thereof, having Formula III

or a pharmaceutically acceptable salt or solvate thereof, wherein

R 7 , R 8 , and R 9 are, independently of each other, selected from the group consisting of fluoro, chloro, halomethyl, and C1-C2-alkoxy, with the proviso that at least one of R 7 , R 8 , and R 9 is not H.

10. The compound according to claim 9 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 7 is fluoro and R 8 and R 9 are H.

11. The compound according to claim 1 , selected from the group consisting of:

12. A pharmaceutical composition, comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.

13. A method for treating a TGR5 related metabolic and/or a gastrointestinal disease, comprising the step of administering a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, to a patient in need thereof, wherein said disease is selected from type II diabetes, obesity, dyslipidemia, atherosclerosis, Irritable Bowel Syndrome (IBS), Crohn's disease, ulcerative colitis, and colitis.

14. The method according to claim 13 , wherein the disease is a metabolic disease selected from the group consisting of type II diabetes, obesity, dyslipidemia, and atherosclerosis.

15. The method according to claim 13 , wherein the disease is a gastrointestinal disease selected from the group consisting of Irritable Bowel Syndrome (IBS), Crohn's disease, ulcerative colitis, and colitis.

16. A method of activating TGR5 receptor in a patient in need of such treatment, comprising the step of administering to said patient an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof.

17. The method according to claim 16 , wherein the compound is an agonist of TGR5 receptor.